TGFB1 and Miyoshi myopathy: In this regard, our data suggest that our new ELISA-based WB NKA assay, probably in combination with the measurement of TGF-β1 levels, has potential value and warrants further development as a supportive diagnostic or prognostic tool for MM in treatment-naïve or posttreatment situations.